Twenty-two Kentucky companies have been designated to receive a total of more than $5 million in new therapeutic discovery project credits and grants from the federal government to help support biomedical research.
The therapeutic discovery project program is targeted to projects that show significant potential to produce new therapies, address unmet medical needs, reduce the long-term growth of healthcare costs, or advance the goal of curing cancer within the next 30 years. The allocation of the credit also reflects which projects show the greatest potential to create and sustain high-quality, high-paying jobs in the United States and to advance competitiveness in the fields of life, biological and medical sciences. The U.S. biotechnology industry currently employs 1.3 million workers and continues to be a key growth engine for the economy.
“We can’t afford to see promising discoveries discarded or innovative businesses move overseas,” said Secretary of Health and Human Services Kathleen Sebelius. “Thanks to the funding provided today, firms can avoid these roadblocks and continue to do business right here in the U.S.”
Kentucky Companies Awarded Federal Grants and Credits through the Therapeutic Discovery Program
• Advanced Genomic Technology LLC, Louisville
• ALLTranz Inc., Lexington
• ALT BioScience LLC, Lexington
• Apellis Pharmaceuticals Inc., Louisville
• ApoImmune Inc., Louisville
• Assenti LLC, Louisville
• Bexion Pharmaceuticals LLC, Covington
• CeeLA Naturals, Louisville
• CTI Science Inc., Lexington
• EndoProTech Inc., Louisville
• Kentucky Pharmaceuticals Inc., Louisville
• NeoCytex Biopharma Inc., Covington
• OrthoData Inc., Louisville
• Potentia Pharmaceuticals Inc., Louisville
• Pradama Inc., Louisville
• Re-Borne Inc., Simpsonville
• Regenerex LLC, Louisville
• RhinoCyte Inc., Louisville
• Summit Biosciences Inc., Lexington
• Suregene LLC, Louisville
• US WorldMeds LLC, Louisville
• Vindico NanoBio Technology Inc., Lexington
Add Comment